Orexo’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Orexo is a specialty pharmaceutical company that focuses on developing druga for the treatment of opioid dependence. Read more

Nikolaj Sorensen's photo - President & CEO of Orexo

President & CEO

Nikolaj Sorensen

CEO Approval Rating





PublicSIX Swiss ExchangeORX









Missing a competitor? Contribute!

BioInvent is seen as one of Orexo's top competitors. BioInvent was founded in 1996, and is headquartered in Lund, Skåne län. BioInvent operates in the Biotechnology industry. BioInvent generates $81.8M less revenue vs. Orexo.

NeuroVive is a top competitor of Orexo. NeuroVive was founded in 1998, and its headquarters is in Lund, Skåne län. Like Orexo, NeuroVive also operates in the Pharmaceuticals industry. NeuroVive has 119 fewer employees than Orexo.

Active Biotech is Orexo's #3 rival. Active Biotech was founded in Lund, Skåne län} in 1996. Active Biotech competes in the Biotechnology industry. Compared to Orexo, Active Biotech generates $86.8M less revenue.


Help the Owler community know more

Competitor - 1/1

Is Mitobridge a competitor of Orexo?

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue


Orexo's revenue is the ranked 3rd among it's top 10 competitors. The top 10 competitors average 79.3M. Over the last three quarters, Orexo's revenue has decreased by 25.8%. Specifically, in Q1 2020's revenue was $17.5M; in Q4 2019, it was $26.6M; in Q3 2019, it was $23.6M.


No recent acquisitions found related to Orexo


No recent investments found related to Orexo

Orexo News

August 31, 2020MarketScreener

and Lyfebulb Announce the Finalists and Jury for the 2020 Innovation Challenge in Substance Use Disorders

(marketscreener.com) UPPSALA, Sweden and NEW YORK, Sept. 1, 2020 /PRNewswire/ -- Orexo, a Swedish pha... See more »
August 10, 2020FinanzNachrichten

Orexo receives paragraph IV Notice Letter for ZUBSOLV in the US

UPPSALA, Sweden, Aug. 10, 2020 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today ann... See more »
July 16, 2020BioSpace

Orexo Interim Report Q2 2020

US launch of the scientifically proven digital therapies deprexis® July 1 and forthcoming launch of v... See more »
July 13, 2020MobiHealthNews

Swedish pharma company Orexo rolls out digital therapeutics for depression, alcohol use disorder

The company is also looking to fast-track its opioid use disorder therapy, thanks to relaxed FDA guid... See more »
July 2, 2020FinanzNachrichten

Orexo Launches Deprexis and Vorvida in the US and Provides Updated Financial Guidance

FDA's "Enforcement Policy" and Orexo's strong financial position enable investments in an accelerated... See more »
June 30, 2020FinanzNachrichten

Positive Results from Human PK Study Assessing Orexo's Intranasal Nalmefene Formulations for Opioid Overdose Reversal

Preliminary data indicate extensive and rapid absorption of OX125 across all formulations Positive re... See more »
June 17, 2020BioSpace

Orexo and Lyfebulb Announce Call for Digital Solutions to Treat Substance Use Disorder

Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies, an... See more »

Orexo Press Releases

November 8, 2019centralcharts

Orexo to Present at Jefferies 2019 Healthcare Conference

Orexo to Present at Jefferies 2019 Healthcare Conference PR Newswire UPPSALA, Sweden, Nov. 8, 2019 UP... See more »
January 11, 2019Central Charts

Actavis Infringes Orexo's Long Term Zubsolv® U.S. Patent ´330

Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction a... See more »
January 10, 2019CENTRALCHARTS

Actavis Infringes Orexo's Long Term Zubsolv® U.S. Patent ´330

Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction a... See more »
October 25, 2018PR Newswire

Orexo - Interim Report Q3 2018

UPPSALA, Sweden, Oct. 25, 2018 /PRNewswire/ -- The win in the patent litigation strengthen Orexo's lo... See more »
November 30, 2017GlobeNewswire

Listing of bond loan issued by Orexo AB (publ) on STO Corporate Bonds (796/17)

Nasdaq Stockholm decides to officially list 1 bond loan issued by Orexo AB with effect from 2017-12-0... See more »
November 22, 2017streetinsider

Orexo Completes Early Redemption of Existing Bond Loan

Orexo AB (publ.) (the "Company") today announces that the Company, in accordance with Orexo's press r... See more »
September 1, 2016NewsMaker

Ischemia Reperfusion Injury Pipeline Landscape and Therapeutics under Development Market Review 2016 H2

Ischemia Reperfusion Injury pipeline therapeutics constitutes close to 60 molecules. Out of which app... See more »

Orexo Videos


P.O. Box 303

Uppsala, Uppsala län751 05


Driving Directions »

Trending Companies




Orexo is a specialty pharmaceutical company that focuses on developing druga for the treatment of opioid dependence. Orexo was founded in 1995. Orexo's headquarters is located in Uppsala, Uppsala län, SE 751 05. Orexo's President & CEO, Nikolaj Soren...


Orexo's President & CEO, Nikolaj Sorensen, currently has an approval rating of 68%. Orexo's primary competitors are BioInvent, NeuroVive & Active Biotech.



Frequently Asked Questions about Orexo

  1. When was Orexo founded?

    Orexo was founded in 1995
  2. Who is Orexo's CEO?

    Orexo's CEO is Nikolaj Sorensen
  3. How much revenue does Orexo generate?

    Orexo generates $89.3M in revenue
  4. How much funding does Orexo have?

    Orexo has historically raised $0 in funding
  1. Where is Orexo's headquarters?

    Orexo's headquarters is in Uppsala Uppsala län, SE
  2. How many employees does Orexo have?

    Orexo has 128 employees
  3. What sector does Orexo operate in?

    Orexo is in Pharmaceuticals
  4. Who are Orexo's competitors?

    Orexo's top competitors are BioInvent, NeuroVive, Active Biotech